SHENZHEN, China, Dec. 2 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com) and its China based subsidiary Mellow Hope announce that HTDS acquired another order of freeze-dried Hepatitis A Vaccine, inactivated (MEVAC-A) for India. The order is due in India at the beginning of December 2009. The HTDS' India sales team outperformed in past months and signals a good sales base for the start of 2010.
Mellow Hope will deliver another order of 49,000 doses of freeze-dried Hepatitis A Vaccine (MEVAC-A) to India in December 2009. The sales of Mellow Hope's MEVAC-A vaccine in India increased at a steady rate in 2009, and HTDS forecasts that this trend will continue in 2010.
HTDS' CEO Terry Yuan said, " The sales team in India has formed a marketing strategy that had proved itself highly effective. Looking at the first 3 quarters of MEVAC-A vaccine sales in India, the sales team outperformed throughout and show a solid sales increase. We analyzed the team's year-round results and we see a growing trend for the vaccine sales in India. We believe that this trend will hold its momentum in 2010 and increase HTDS' overall sales next year."
Hard to Treat Diseases (HTDS) is also a parent company with operations in Serbia based Slavica Biochem (http://www.slavicabiochem.com/). This company focuses on the enhancement and modification of existing and approved medications as well as on cancer research. The MindUp cancer research (http://www.mindupbioresearch.com/) has been delivering groundbreaking results on the international level.
To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters, www.minamargroup.com
SOURCE Hard to Treat Diseases
Advertisement
Mellow Hope will deliver another order of 49,000 doses of freeze-dried Hepatitis A Vaccine (MEVAC-A) to India in December 2009. The sales of Mellow Hope's MEVAC-A vaccine in India increased at a steady rate in 2009, and HTDS forecasts that this trend will continue in 2010.
Advertisement
HTDS' CEO Terry Yuan said, " The sales team in India has formed a marketing strategy that had proved itself highly effective. Looking at the first 3 quarters of MEVAC-A vaccine sales in India, the sales team outperformed throughout and show a solid sales increase. We analyzed the team's year-round results and we see a growing trend for the vaccine sales in India. We believe that this trend will hold its momentum in 2010 and increase HTDS' overall sales next year."
Hard to Treat Diseases (HTDS) is also a parent company with operations in Serbia based Slavica Biochem (http://www.slavicabiochem.com/). This company focuses on the enhancement and modification of existing and approved medications as well as on cancer research. The MindUp cancer research (http://www.mindupbioresearch.com/) has been delivering groundbreaking results on the international level.
To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters, www.minamargroup.com
SOURCE Hard to Treat Diseases
